SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001213900-24-052234
Filing Date
2024-06-13
Accepted
2024-06-13 07:01:34
Documents
14
Period of Report
2024-06-13
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0207791-8k_aldeyra.htm   iXBRL 8-K 26621
2 ALDEYRA THERAPEUTICS, INC. PRESS RELEASE DATED JUNE 13, 2024 ea020779101ex99-1_aldeyra.htm EX-99.1 13804
  Complete submission text file 0001213900-24-052234.txt   219528

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE aldx-20240613.xsd EX-101.SCH 3012
4 XBRL LABEL FILE aldx-20240613_lab.xml EX-101.LAB 34240
5 XBRL PRESENTATION FILE aldx-20240613_pre.xml EX-101.PRE 22357
17 EXTRACTED XBRL INSTANCE DOCUMENT ea0207791-8k_aldeyra_htm.xml XML 3688
Mailing Address 131 HARTWELL AVENUE SUITE 320 LEXINGTON MA 02421
Business Address 131 HARTWELL AVENUE SUITE 320 LEXINGTON MA 02421 781-761-4904
Aldeyra Therapeutics, Inc. (Filer) CIK: 0001341235 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36332 | Film No.: 241039998
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)